• Роль Витекса священного (Vitex agnus castus) в гинекологической эндокринологии
ru К содержанию

Роль Витекса священного (Vitex agnus castus) в гинекологической эндокринологии

HEALTH OF WOMAN. 2016.10(116):24–27
 

Роль Витекса священного (Vitex agnus castus) в гинекологической эндокринологии
 

Вуттке В., Зайдлова-Вуттке Д., Ярри Г., Артымук Н.

Кафедра эндокринологии Университета Геттингена, Германия

ГБОУ ВПО Кемеровская государственная медицинская академия Минздравсоцразвития РФ

Опубликовано: Гинекология. – Т. 14; №1.


Экстракты из сушеных плодов Витекса священного (Vitex agnus castus – VAC) содержат дофаминергические субстанции, которые ингибируют секрецию пролактина в гипофизе. Возникновение не только предменструальной мастодинии, но и, как доказано в последнее время, фиброзно-кистозной мастопатии, связаны с действием пролактина. Так, у многих пациенток, у которых в стрессовых ситуациях и в фазе глубокого сна происходит усиленный выброс пролактина, развиваются указанные состояния. Так называемая латентная гиперпролактинемия может также привести к лютеиновой недостаточности и бесплодию. В этих случаях терапия с помощью VAC может оказывать стимулирующее влияние на фертильность.


Ключевые слова: Витекс священный, Vitex agnus castus, мастодиния, предменструальный симптом, лютеиновая недостаточность, пролактин, дофамин.


Литература:
1. Wuttke W, Gorkow С, Seidlova-Wuttke D. Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study.Menopause 2006; 13:185–96. https://doi.org/10.1097/01.gme.0000174470.44822.57; PMid:16645532

2. Wuttke W, Jarry H, Christoffel V et al. Chaste tree (Vitex agnus-castus) – pharmacology and clinical indications. Phytomedicine 2003; 10:348–57. https://doi.org/10.1078/094471103322004866ж PMid:12809367

3. Gorkow C, Wuttke W. Evidence of efficacy of Vitex agnus castus preparations. Phytopharmaka. – 1999; p. 189–208.

4. Halaska M, Raus К, Bкles P et al. Treatment of cyclical mastodynia using an extract of Vitex agnus castus: results of a double-blind comparison with a placebo. Ceska Gynekol 1998; 63:388–92.

5. Wuttke W, Splitt G, Gorkow С et al. Behandlung zyklusabhдngiger Brustschmerzen mit einem Agnus ca-stus-haltigen Arzneimittel-Ergebnisse einer rando-misierten, plazebokontrollierten Doppelblindstudie. Geburtsh и Frauenheilk 1997; 57:569–74. https://doi.org/10.1055/s-2007-1023139

6. Kubist a E, Muller G, Sponaf. Treatment of mastopathies with cyclic mastodynia. Clinical results and hormonal profiles.RevFr Gynecol Obstet 1987; 82:221–7.

7. Kumar S, Mansel RE, Hughes LE et al. Prediction of response to endocrine therapy in pronounced cyclical mastalgia using dynamic tests of prolactin release. Clin Endocrinol (Oxf) 1985; 23:699–704. https://doi.org/10.1111/j.1365-2265.1985.tb01131.x

8. Suginami H, Ito T, Hamada К et al. Serum prolactin levels during sleep and in metoclopramide stimulation in normoprolactinemic anovulation and ovulation induction with bromocriptine. Nippon Sanka Fujinka Gakkai Zasshi 1986; 38: 728–34.

9. Wuttke W, Pitzel L, Seidlova-Wuttke D et al. LH pulses and the corpus luteum: the luteal phase deficiency LPD. Vitam Horm 2001; 63: 131–58. https://doi.org/10.1016/S0083-6729(01)63005-X

10. Freeman ME, Kanyicska B, Lerant A et al. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000; 80:1523–631.

11. Dogliotti L, Mansel RE. Bromocriptine treatment of cyclical mastalgia/fibrocystic breast disease: update on the European trial. Br J Clin Pract Suppl 1989; 68:26-32; dis. 49–53.

12. Nazli K, Syed S, Mahmood MR et al. Controlled trial of the prolactin inhibitor bromocriptine (Parlodel) in the treatment of severe cyclical mastalgia. Br J Clin Pract 1989; 43:322–7.

13. Schwibbe M BD, Wuttke W. EEG and psycho-logical effects oflisuride in women with premenstrueal tension. Lisurides and Other Dopmanine Agonists. Calne et al. 1983.

14. Milewicz A, Gejdel E, Sworen H et al. Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study. Arzneimittelforschung 1993; 43: 752–6.

15. Wuttke WGC, Jarry H. Dopaminergic compounds in Vitex agnus castus. Phyto-Pharmaka-Forschung und klinische Anwendung 1995; p. 81–91.

16. Jarry H, Leonhardt S, Gorkow С et al. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol 1994; 102: 448–54. https://doi.org/10.1055/s-0029-1211317; PMid:7890021

17. Ono M, Nagasawa Y, Iked T et al. Three new diterpenoidsfrom the fruit of Vitex agnus castus. Chem Pharm Bull (Tokyo) 2009; 57:1132–5. https://doi.org/10.1248/cpb.57.1132

18. Christoffel V, Spengler B, Jarry H et al. Prolactin inhibiting dopaminergic activity of diterpenes from Vitex agnus castus Phytopharmaka 1999; p. 209–14.

19. Artymuk NV. Vitex agnus castus extract administered for luteal-phase defect treatment. GReproduktionsmedт Endokrinol 2010; 7:362.

20. Gerhard, Patek A, Monga В et al. MastodynonR bei weiblicher Sterilitдt. Forsch Komplementarmed 1998; 5:272–8. https://doi.org/10.1159/000021154; PMid:9973660

21. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised,placebo controlled study. BMJ 2001; 322: 134–7. https://doi.org/10.1136/bmj.322.7279.134; PMid:11159568 PMCid:PMC26589

22. Prilepskaya VN. Vitex agnus castus: Successful treatment of moderate to severe premenstrual syndrome. Maturitas 55S 2006; p. 55–63.

23. Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol 2003; 18:191–5. https://doi.org/10.1002/hup.470; PMid:12672170

24. Bogorad RL, Courtillot C, Mestayer С et al. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc Natl Acad Sсі USA 2008; 105:14533–8. https://doi.org/10.1073/pnas.0800685105; PMid:18779591 PMCid:PMC2567233

25. Courtillot C, Chakhtoura Z, Bogorad R et al. Characterization of two constitutively active prolactin receptor variants in a cohort of 95 women with multiple breastfibroadenomas. G Clin Endocrinol Metab 1995; p. 271-9.

26. Daniele С, Thompson Coon J, Pittler MH et al. Vitex agnus castus: a systematic review of adverse events. DrugSaf2005; 28:319-32. https://doi.org/10.2165/00002018-200528040-00004